Remdesivir in COVID-19: Indication of considerable added benefit for a part of the patients
COVID-19 patients with pneumonia who do not yet require high-flow oxygen therapy benefit from remdesivir: they recover more quickly and the risk of dying is reduced. These benefits are not proven for individuals with more severe disease.
2021-07-06
(Press-News.org) Since July 2020, remdesivir has been conditionally approved in Europe for the treatment of coronavirus disease (COVID-19) in adults and adolescents aged 12 years and older with pneumonia who require supplemental oxygen but no invasive ventilation. In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now investigated whether the drug, which was originally developed for the treatment of Ebola virus disease, offers these patients an added benefit compared to the appropriate comparator therapy (here: therapy according to physician's choice).
This investigation yielded an indication of a considerable added benefit of remdesivir compared to the appropriate comparator therapy for adults with pneumonia who are moderately ill with COVID-19 and who "only" received low-flow oxygen therapy at the start of treatment. However, an added benefit has not been proven for adults with more severe COVID-19 disease and pneumonia who already had to be treated with high-flow oxygen or other non-invasive ventilation at the start of treatment.
Study data for adolescents with COVID-19 disease were not available. As the mortality risks of this disease strongly depend on age, the results of the benefit assessment observed for adults cannot be transferred to adolescents either, so that an added benefit is not proven for this group.
Three RCTs conducted at the beginning of the Corona pandemic
The benefit assessment of remdesivir is based on the data from three randomized controlled trials (RCTs) with altogether 1,895 COVID-19 patients, from which subgroups with a total of 958 patients are relevant for the assessment. Patients in the comparator arm received treatment options currently available for diseases such as COVID-19.
In general, it can be assumed that the treatment of hospitalized patients with COVID-19 has improved since the beginning of the pandemic (e.g. administration of dexamethasone). Therefore, the treatment of COVID-19 disease in the three studies included can only be transferred to the current care situation to a limited extent. This uncertainty was taken into account in the certainty of conclusions of the results.
Positive effects in moderately ill patients
For the subpopulation of adult COVID-19 patients with pneumonia and low-flow oxygen therapy at the start of treatment, the overall consideration shows predominantly positive effects of remdesivir compared to standard therapy: The affected individuals have a higher chance of survival and they recover more quickly. Although usable data on the side effects are lacking, the available information does not suggest any negative effects to an extent that could call an added benefit into question.
In summary, there is an indication of considerable added benefit of remdesivir versus the treatment according to physician's choice specified by the Federal Joint Committee (G-BA) as appropriate comparator therapy for adults with COVID-19 disease with pneumonia requiring low-flow oxygen therapy at the start of treatment.
Neither positive nor negative effects in patients with more severe disease
For the subpopulation of adults with COVID-19 disease with pneumonia and high-flow oxygen therapy at the start of treatment, the overall consideration shows neither positive nor negative effects of remdesivir compared with the treatment options available to date. An added benefit of remdesivir versus the appropriate comparator therapy can therefore not be derived for this group of patients with more severe COVID-19 disease.
Treating the right patients at the right time with remdesivir
"Rarely has a new drug been so much in the focus of the global public as remdesivir at the beginning of the COVID-19 pandemic," says Thomas Kaiser, Head of IQWIG's Drug Assessment Department. "Today, almost exactly one year after the European Commission granted a conditional market approval, we know: COVID-19 patients with pneumonia who only need low-flow oxygen therapy at the start of treatment benefit considerably from treatment with remdesivir. However, the drug provides no benefit to patients with more severe disease. It is crucial to treat the right patients at the right time with the drug."
G BA decides on the extent of added benefit
The dossier assessment is part of the early benefit assessment according to the Act on the Reform of the Market for Medicinal Products (AMNOG) supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.
More English-language information will be available soon (extracts of the dossier assessment as well as easily understandable information on informedhealth.org). If you would like to be informed when these documents are available, please send an e-mail to info@iqwig.de.
INFORMATION:
ELSE PRESS RELEASES FROM THIS DATE:
2021-07-06
In a study published in Physical Review Letters, academician GUO Guangcan's team from University of Science and Technology of China of the Chinese Academy of Sciences made progress in the open quantum system research. This team, collaborating with Austrian theoretical physicist Philip Taranto, demonstrated the non-Markovianity in the multi-step evolution of the open quantum system, and proved the measurement-dependent property of quantum memory effects.
In quantum information science, it is crucial to understand and control the memory effects for the development of quantum technology. For the coupling of the system and environment, the evolution of open quantum system presents the non-Markovianity, ...
2021-07-06
Faba beans have been an excellent source of food protein since pre-historic times, but about 5% of people, mostly from regions where malaria has been endemic and who carry a certain mutation, can't eat them. Now, an international team of researchers, led by the Universities of Helsinki and Copenhagen as well as Luke Natural Resources Institute Finland, has identified the gene responsible for the production of vicine and convicine, which are harmful to these people. In the work published in Nature Plants, the team reports that the VC1 gene plays a central role in the biosynthesis these compounds.
Faba beans - Pythagoras and his followers avoided them and Roman priests of Jupiter associated them with death. ...
2021-07-06
A research team led by Prof. CHEN Xianhui from University of Science and Technology of China of the Chinese Academy of Sciences (CAS) found an unusual competition between charge density wave (CDW) and superconductivity in CsV3Sb5, a layered kagome metal, which provides key experimental evidence for understanding novel CDW and superconductivity. The result was published on Nature Communications and recommended as featured article.
Traditional superconductivity and CDW are two different electronic states, which both originate from electron phonon coupling and Fermi instability. In the conventional coexistence image of CDW and superconductor, after entering the CDW state, the energy gap is opened due to the nesting of Fermi surface, resulting in the loss of density ...
2021-07-06
The stage is set for a new carbon storage economy to emerge along the Gulf Coast, according to a study led by The University of Texas at Austin, with the region offering ample opportunities to capture and store carbon, and recent state and federal incentives giving an added push to get started.
Carbon capture and storage, or CCS, is a technology that keeps CO2 out of the atmosphere by capturing emissions and storing them deep underground. It can help fight climate change by lowering industrial emissions now while renewable energy sources are being developed, said Tip Meckel, a senior research scientist at the Gulf Coast Carbon Center, a research group at the UT Bureau ...
2021-07-06
Since the discovery of the first fossil remains in the 19th century, the image of the Neanderthal has been one of a primitive hominin. People have known for a long time that Neanderthals were able to effectively fashion tools and weapons. But could they also make ornaments, jewellery or even art? A research team led by the University of Göttingen and the Lower Saxony State Office for Heritage has analysed a new find from the Unicorn Cave (Einhornhöhle) in the Harz Mountains. The researchers conclude that, in fact, Neanderthals, genetically the closest relative to modern humans, had remarkable cognitive abilities. The results of the study were published in Nature Ecology and Evolution.
Working with the Unicornu Fossile society, the scientists ...
2021-07-06
Human activities like the burning of coal and fossil fuels have caused CO2 to accumulate in the atmosphere, which has significantly affected the Earth's climate. As a result, several scientists are looking for ways to convert CO2 into other valuable organic products, such as 1-butanol, which has shown promise as an alternative fuel for vehicles. This could help reduce our dependence on fossil fuels.
One method of obtaining useful compounds is by the electrochemical reduction reaction (CO2RR). Researchers have developed metal-based catalysts that can fulfill this task. However, there is a caveat: most of these catalysts are expensive and produce a variety of products during the reaction, ...
2021-07-06
MIAMI--A new study led by scientists at the University of Miami (UM) Rosenstiel School of Marine and Atmospheric Science is the first to document what coral genes are doing in response to a disease that is rapidly killing corals throughout Florida and the Caribbean. The findings can help to better understand coral immune system as new diseases emerge as the ocean warm.
The collaborative effort between researchers at the UM Rosenstiel School, Mote Marine Laboratory and the Smithsonian Marine Station is the first to document a gene expression response of corals to stony coral tissue loss disease and that the disease causes a shared immune response in at least two coral species -- mountainous star coral (O. faveolata) and great star coral ...
2021-07-06
Metal-organic frameworks (MOF) are crystalline porous organic-inorganic hybrid materials that, by filling its pores with guest molecules, can create functionalities through interactions between the organic-inorganic based frameworks of MOF (host) and its guest molecules. This host-guest chemistry has the potential to bring "designable" electrical properties, allowing for a material to be organized in ways never before possible - paving the way for the next-generation of thin-film smart devices.
"However, most MOFs exhibit poor electrical conductivity", states Professor Masahide Takahashi, ...
2021-07-06
Philadelphia and Santiago -A new study published in The Lancet Global Health showed that establishing safe nurse staffing standards in hospitals in Chile could save lives, prevent readmissions, shorten hospital stays, and reduce costs.
The study, by the Center for Health Outcomes and Policy Research (CHOPR) at the University of Pennsylvania School of Nursing, and the Universidad de los Andes - Chile School of Nursing, found very large variations in patient to nurse staffing across 40 hospitals located throughout Chile. Nurse staffing was significantly ...
2021-07-06
SAN ANTONIO -- July 6, 2021 -- Scientists have used data from the Southwest Research Institute-led Magnetospheric Multiscale (MMS) mission to explain the presence of energetic heavy elements in galactic cosmic rays (GCRs). GCRs are composed of fast-moving energetic particles, mostly hydrogen ions called protons, the lightest and most abundant elements in the universe. Scientists have long debated how trace amounts of heavy ions in GCRs are accelerated.
The supernova explosion of a dying star creates massive shockwaves that propagate through the surrounding space, accelerating ions in their path to very high energies, creating ...
LAST 30 PRESS RELEASES:
[Press-News.org] Remdesivir in COVID-19: Indication of considerable added benefit for a part of the patients
COVID-19 patients with pneumonia who do not yet require high-flow oxygen therapy benefit from remdesivir: they recover more quickly and the risk of dying is reduced. These benefits are not proven for individuals with more severe disease.
